Compare Regeneron Pharmaceuticals Inc (REGN) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs United States Oil ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while United States Oil ETF trades at $132.29. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while United States Oil ETF pays none, and United States Oil ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | USO | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $152.96 |
52-Week Low | $545.46 | $66.17 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
USO trades at $125.51, up 1.25% with a bullish technical signal driven by moving averages. Recent news highlights Middle East supply disruptions as a key catalyst, with oil prices testing resistance levels. The stock shows strong momentum but overbought RSI readings suggest caution near-term.
Outlook remains positive given geopolitical tensions supporting oil prices, though elevated RSI indicates potential pullback risk. Key support sits at $124, with resistance at $127. Investors face volatility from supply shocks and inflation concerns, requiring careful position management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
